In Person

OBJECTIVES: Upon completion of this activity, the participant should be able to:  

  1. Define the syndrome of heart failure.
  2. Explain the prognosis of heart failure syndrome.
  3. Learn about the pharmacological interventions to improve outcomes including decrease heart failure exacerbations.

FACULTY DISCLOSURE:  Ebere Chukwu, MD, is a speaker with Alnylam Pharmaceuticals and was a speaker with Boehringer Ingelheim. 

PLANNER DISCLOSURE: The planners have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Tove Goldson, MD at tove.goldson@bswhealth.org.

Session date: 
01/22/2025 - 6:00pm to 7:00pm CST
Location: 
Baylor Scott & White Medical Center - Temple
2401 S 31st Street
Temple, TX 76508
United States
  • 1.00 AMA PRA Category 1 Credit
    The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • 1.00 Attendance

Please login or register for this course.